Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Teva Pharma Industries Ltd ADR (TEVAN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
270.04 +28.04    +11.59%
09/05 - Closed. Currency in MXN ( Disclaimer )
Type:  Equity
Market:  Mexico
ISIN:  US8816242098 
S/N:  881624209
  • Volume: 20
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 270.04 - 270.04
Teva ADR 270.04 +28.04 +11.59%

TEVAN Balance Sheet

 
Featured here, the Balance Sheet for Teva Pharma Industries Ltd ADR, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Collapse All
Period Ending: 2024
31/03
 2023
31/12
 2023
30/09
 2023
30/06
Total Current Assets 12297 12485 11425 12088
Cash and Short Term Investments 2991 3226 2249 2669
Cash - - - -
Cash & Equivalents 2991 3226 2249 2669
Short Term Investments - - - -
Total Receivables, Net 3456 3408 3385 3539
Accounts Receivables - Trade, Net 3456 3408 3385 3539
Total Inventory 3949 4021 4051 4109
Prepaid Expenses 1336 1255 1168 1228
Other Current Assets, Total 565 575 572 543
Total Assets 42773 43479 42088 43095
Property/Plant/Equipment, Total - Net 5982 6147 6028 6130
Property/Plant/Equipment, Total - Gross - 11784 - -
Accumulated Depreciation, Total - -5637 - -
Goodwill, Net 17007 17177 16885 17118
Intangibles, Net 5056 5387 5525 5738
Long Term Investments - 8 - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 471 463 477 443
Other Assets, Total 3018 3000 2986 2691
Total Current Liabilities 13792 12247 11394 11843
Accounts Payable 2439 2602 2280 2508
Payable/Accrued - - - -
Accrued Expenses 3276 5525 5274 5014
Notes Payable/Short Term Debt 3060 - 500 -
Current Port. of LT Debt/Capital Leases - 1769 979 1980
Other Current liabilities, Total 5017 2351 2361 2341
Total Liabilities 35230 35353 34577 35387
Total Long Term Debt 16584 18184 18495 18698
Long Term Debt 16584 18161 18495 18698
Capital Lease Obligations - 23 - -
Deferred Income Tax 569 606 544 534
Minority Interest 265 620 582 656
Other Liabilities, Total 960 3696 3062 3656
Total Equity 7543 8126 7511 7708
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 7278 57 57 57
Additional Paid-In Capital - 27807 27780 27748
Retained Earnings (Accumulated Deficit) - -13534 -13870 -13950
Treasury Stock - Common - -4128 -4128 -4128
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 265 -2076 -2328 -2019
Total Liabilities & Shareholders' Equity 42773 43479 42088 43095
Total Common Shares Outstanding 1123 1121.09 1120.97 1120.65
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd DRC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni 18 hours ago
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
One day to ER of Q1
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New price target of 17$ by Barclays analyst
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1% on a Friday with 9.13M volume someone is buying.
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
Reply
0 0
Report
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
long trend starting
Reply
5 0
Report
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hopefully ! Ive been w8ing for it for 3 y xD
Reply
2 0
Report
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11,40 will hold as celling or convert to floor :)?
Reply
0 0
Report
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
Reply
2 0
Report
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
25 next year seems quite doable
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email